ClinicalTrials.gg
Status unknownNCT05409326Updated Jun 8, 2022

A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects

A Phase 1 interventional study of TQH2722 injection and Placebo to match TQH2722 in Atopic Dermatitis, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-08.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
156th of 190
48 · median 164
Started
2022
with 21 others
Phase 1
38 of 206
14 open now
Registered
44th of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 156th largest by planned enrollment of the 190 interventional ones that give a count, is one of 22 that started in 2022, is one of 38 in phase 1, and was the 44th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled trial design was used to assess the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics, and immunogenicity of TQH2722 injection in healthy subjects.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 The was signed before the trial, fully understood the purpose and process of the trial and the possible adverse reactions.
  • 2 Aged 18 \~ 60 years old (including the critical value), both male and female;
  • 3 ≥ 45 kg for females and ≥ 50 kg for males with a (BMI) between 19 and 26 kg/m2 inclusive, BMI = weight (kg)/height2 (m2)
  • 4 The subject is able to communicate well with the investigator, voluntary and able to understand and follow protocol procedures to complete the study;
  • 5 The subject agrees not to have a childbearing plan from the date of signing the informed consent form to 6 months after the last dose, and must use effective non-drug with a partner of ;
  • 6 Normal physical examination, vital signs or abnormal physical examination, vital signs without clinical significance

Exclusion criteria

Exclusion Criteria:

  • 1 Females who are pregnant, lactating or have unprotected sex within two weeks prior to screening;
  • 2 Past medical history or current cardiac, endocrine, metabolic, renal, hepatic, gastrointestinal, skin, infection, hematological, neurological or psychiatric diseases/abnormalities, or related chronic diseases, or acute diseases, and the investigator evaluated that the subject was not suitable for the trial;
  • 3 People who have abnormal and results in vital signs, physical examination, laboratory tests, eye examination, 12-lead and X-ray during screening period;
  • 4 Subjects Positive for Any of Virus Surface Antigen (HBsAg), Virus Antibody (Anti-HCV), Antibody (Anti-HIV), and Treponema Pallidum Antibody (Anti-TP);
  • 5 Clinically significant respiratory infection requiring antibiotic or antiviral therapy within 7 days prior to randomization;
  • 6 People who received surgical operation within 4 weeks prior to screening, or planned to receive surgical operation during the study period;
  • 7 People who participated in other clinical trials and took the study drug within 3 months before screening;
  • 8 Received immunoglobulins or blood products within 30 days prior to randomization;
  • 9 Blood loss or blood donation of more than 400 mL within 2 months prior to randomization;
  • 10 People who have potential difficulty in blood collection, or have a history of halo needles or blood sickness;
  • 11 A history of allergic reactions to another therapeutic monoclonal antibody or biologic agent therapy, or any clear history of drug or food allergies, particularly those with allergies to similar components to the drug in this trial;
  • 12 People who have received or are planning to receive live-reduced or active vaccines during the 30 days prior to randomization and the entire study period (including the follow-up period);
  • 13 Smoking more than 5 cigarettes per day or using equivalent amounts of nicotine or nicotine-containing products during the 6 months prior to randomization and the entire study period (including the follow-up period);
  • 14 People who had long-standing alcohol abuse or alcohol consumption of more than 14 units (1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) of alcohol per week during the 3 months prior to screening and the entire study period (including the follow-up period), or those who tested positive for alcohol breath;
  • 15 People with a history of substance abuse or positive urine drug screening;
  • 16 Received any marketed or research biologics within 4 months or 5 half-lives (whichever is longer) prior to randomization;
  • 17 Taking any prescription, over-the-counter and herbal medicines within 4 weeks prior to randomization, with the exception of vitamin products;
  • 18 Use of any systemic cytotoxicity or systemic within 6 months prior to randomization or during the study period, or any local cytotoxin or local immunosuppressive drug within 30 days or 5 half-life periods (whichever is longer) prior to randomization or during the study period;
  • 19 Parasitic infection is associated and is excluded if any of the following are met:

    • During the screening period, the stool routinely checks positive for eggs;
    • History of parasitic infection within 6 months prior to the screening period;
    • Have traveled or planned to travel to endemic parasitic infection areas (including but not limited to Southeast and South-West Asia, South America and Africa) within 6 months prior to screening visits;
  • 20 Any situation in which the investigator believes that this poses a safety risk to the subject in the trial or may interfere with the conduct of the study, or that the investigator believes that the subject may not be able to complete the study or may not be able to comply with the requirements of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    TQH2722 injection

    Participants will receive single dose of TQH2722 injection under fasted condition (Single Ascending Dose(SAD) Cohorts 50mg, 150mg, 300mg, 600mg, 1200mg) on Day 1, or will receive multiple doses of TQH2722 injection once every 14 days under fasted condition (Multiple-Dose Administration (MAD) Cohort 150mg, 600mg) on Day 1-43.

    Drug: TQH2722 injection

  • Placebo comparator
    Placebo to match TQH2722

    Participants will receive single dose of matching placebo under fasted condition (Single Ascending Dose(SAD) Cohorts 50mg, 150mg, 300mg, 600mg, 1200mg) on Day 1, or will receive multiple doses of matching placebo once every 14 days under fasted condition (Multiple-Dose Administration (MAD) Cohort 150mg, 600mg) on Day 1-43.

    Drug: Placebo to match TQH2722

Interventions

  • TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.

  • DrugPlacebo to match TQH2722

    TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.

06

What researchers measure

Primary outcomes

  1. Adverse events (AE)

    Incidence and severity of adverse events (AE) .

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  2. Serious adverse events (SAE)

    Incidence and severity of Serious adverse events (SAE).

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  3. Blood biochemistry

    Abnormal indicators of blood biochemistry.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  4. Coagulation function

    Abnormal indicators of coagulation function.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  5. Blood routine

    Abnormal indicators of blood routine.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  6. Urinalysis

    Abnormal indicators of urinalysis.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  7. Blood pressure

    Abnormal values of blood pressure

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  8. Pulse

    Abnormal values of blood pulse.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  9. Body temperature

    Abnormal values of blood body temperature.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  10. Skin

    Examination of the skin.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  11. Mucous membranes

    Examination of the mucous membranes.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  12. Lymph nodes

    Examination of the lymph nodes.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  13. Head

    Examination of the head.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  14. Neck

    Examination of the neck.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  15. Chest

    Examination of the chest.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  16. Abdomen

    Examination of the abdomen.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  17. Spine

    Examination of the spine.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  18. Limbs

    Examination of the limbs.

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

  19. 12-lead electrocardiogram

    Abnormal values of 12-lead electrocardiogram

    Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.

Secondary outcomes

  1. Maximum Concentration(Cmax)

    Maximum Concentration

    Time frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.

  2. Minimum Concentration(Cmax)

    Minimum Concentration

    Time frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.

  3. Time to maximum concentration(Tmax)

    Time to maximum concentration following drug administration

    Time frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.

  4. Area under the drug-time curve(AUC)

    Area under the drug-time curve

    Time frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.

  5. Apparent terminal elimination half-life(t1/2)

    Apparent terminal elimination half-life following drug administration

    Time frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.

  6. Apparent volume of distribution(Vd/F)

    Apparent volume of distribution

    Time frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose.

  7. Clearance rate(CL/F)

    Clearance rate

    Time frame: SAD:Before administration,1,4,8,12,24,72,168,240,336,408,504,576,672,840,1008,1176,1344 hours postdose. MAD:Before every administration,1,4,8,12,24,72,168,504,840,1009,1012,1016,1020,1032,1080,1176,1334,1512,1680,1848,2016,2352 hours postdose

  8. Immunoglobulin E(IgE)

    Percentage of changes in serum IgE

    Time frame: SAD:Before administration,168,336,504,672,1008,1344 hours after administration. MAD:Before every administration,336,672,1344 hours after the last administration.

  9. Thymus activation regulates chemokines(TARC)

    Percentage of changes in serum TARC

    Time frame: SAD:Before administration,168,336,504,672,1008,1344 hours after administration. MAD:Before every administration,336,672,1344 hours after the last administration.

  10. Anti-drug antibody (ADA)

    Incidence and titer of anti-drug antibody

    Time frame: SAD:Before administration,336,1344 hours after administration. MAD:Before the first administration;Before the third administration;336,1344 hours after the last administration.

  11. Neutralizing Antibody(Nab)

    Incidence of Neutralizing Antibody

    Time frame: SAD:Before administration,336,1344 hours after administration. MAD:Before the first administration;Before the third administration;336,1344 hours after the last administration.

  12. Injection site response

    Injection site response assessment

    Time frame: Before administration,0.5,1,3,6 hours after administration.

07

Study locations

1 of 1 sites recruiting
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2022; primary completion for Jun 2023, 12 months later.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 12 months is close to that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2022
First posted
Jun 8, 2022
StartEst.
Jun 2022
Primary completionEst.
Jun 2023
CompletionEst.
Aug 2023
Last update
Jun 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05409326
Responsible party
Sponsor
First posted
Jun 8, 2022
Start date
Jun 2022 (estimated)
Primary completion
Jun 2023 (estimated)
Completion
Aug 2023 (estimated)
Last update
Jun 8, 2022

Study contacts

Yu Cao, Doctor
Contact
caoyu1767@126.com
0532-82917310

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQH2722

Start the discussion